Sec Form 4 Filing - STARR CHRISTOPHER M @ Raptor Pharmaceutical Corp - 2013-09-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person STARR CHRISTOPHER M 2. Issuer Name and Ticker or Trading Symbol Raptor Pharmaceutical Corp [ RPTP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O RAPTOR PHARMACEUTICAL CORP., 5 HAMILTON LANDING, SUITE 160 3. Date of Earliest Transaction (MM/DD/YY) 09/16/2013 (Street) NOVATO, CA94949 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/16/2013( 1 ) M 5,000 A $ 2.97 704,370 D Common Stock 09/16/2013( 1 ) M 15,000 A $ 2.83 719,370 D Common Stock 09/16/2013( 1 ) M 5,000 A $ 3.54 724,370 D Common Stock 09/16/2013( 1 ) S 25,000 D $ 14.2072 ( 2 ) 699,370 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock options (right to buy) $ 2.97 09/16/2013( 1 ) M 5,000 03/01/2011( 6 ) 10/11/2020 Common Stock 5,000 $ 0 167,524 ( 9 ) D Stock options (right to buy) $ 2.83 09/16/2013( 1 ) M 15,000 11/26/2006( 4 )( 5 ) 05/25/2016 Common Stock 15,000 $ 0 14,140 ( 9 ) D Stock options (right to buy) $ 3.54 09/16/2013( 1 ) M 5,000 11/22/2010( 7 ) 11/21/2020 Common Stock 5,000 $ 0 340,054 ( 9 ) D Stock options (right to buy) $ 2.02 03/09/2010( 4 )( 8 ) 03/08/2020 Common Stock 46,750 35,548 ( 9 ) D Stock options (right to buy) $ 5.13 03/22/2012( 3 ) 09/21/2021 Common Stock 460,064 460,064 ( 9 ) D Stock options (right to buy) $ 5.49 03/25/2013( 3 ) 09/24/2022 Common Stock 150,000 150,000 ( 9 ) D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other STARR CHRISTOPHER M C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO, CA94949 X Chief Executive Officer Signatures /s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact 09/18/2013 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 13, 2013. ( 2 )This transaction was executed in multiple trades at prices ranging from $13.98 to $14.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 3 )Stock options vest 6/48ths on the six month anniversary of grant date and 1/48th per month thereafter. ( 4 )Fully vested and exercisable. ( 5 )Options vest 6/36ths on the six month anniversary of grant date and 1/36th per month thereafter. ( 6 )Stock options vest starting on September 1, 2010, 6/48ths on March 1, 2011 and 1/48th per month thereafter. ( 7 )Stock option vests 25% immediately and 75% pro rata over 36 months. ( 8 )Options vest 6/48ths immediately and 1/48th per month thereafter. ( 9 )The shares listed as owned in column 9 represent the total shares for each respective option. Previous reports reflected aggregate amounts of option shares in column 9. The holding lines included on this Form 4 are included solely to correct the breakdown of shares among various stock options and are not meant to reflect any change in beneficial ownership of option shares other than those reported as a transaction on this Form 4.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.